Agilent's Premium Valuation Leaves No Room for Another Guidance Disappointment

Agilent Technologies reports fiscal second-quarter 2026 earnings after the close on May 27, with Wall Street expecting EPS of $1.40 and revenue around $1.80 billion. The central question is whether the laboratory instruments maker can sustain the momentum from its raised full-year guidance issued in February, or if tariff headwinds and weather-related disruptions will weigh on results. With the stock trading well below its 100-day and 200-day moving averages and technical signals flashing caution, investors will be watching closely for signs that the company's 4-6% core revenue growth outlook remains intact.

Part 1: Earnings Preview

Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, offering liquid chromatography systems, mass spectrometry instruments, and laboratory workflow solutions. The company reports fiscal Q2 2026 earnings after the close on May 27, with analysts expecting EPS of $1.40 on revenue of approximately $1.80 billion.

The company most recently reported fiscal Q1 2026 EPS of $1.36, which narrowly missed the $1.37 consensus by a penny but still represented 4% year-over-year growth. Comparing the current quarter's $1.40 estimate to the $1.31 reported in Q2 2025 (same quarter last year) implies 6.87% year-over-year growth, suggesting analysts expect continued recovery momentum.

Three key themes define this earnings story:

Tariff Impact and Margin Pressure: In Q1, Agilent's gross margin declined 100 basis points to 53.7% and operating margin fell 50 basis points to 24.6%, primarily due to tariff-related costs. Investors will scrutinize whether these headwinds have intensified or stabilized, and how management is navigating pricing and cost mitigation strategies.

Core Revenue Growth Trajectory: The company delivered 4.4% core revenue growth in Q1 (with a 2.6% currency tailwind boosting reported growth to 7.0%), and management raised full-year core revenue guidance to 4-6%. The question is whether demand trends across life sciences and diagnostics markets remain robust enough to support the upper end of that range.

Guidance Confidence: Management raised full-year EPS guidance by $0.04 to a range of $5.90-$6.04 in February, and provided Q2 EPS guidance of $1.39-$1.42. With the consensus at $1.40 sitting comfortably in that range, investors will watch for any adjustment to the full-year outlook based on second-quarter performance and visibility into the second half.

Analysts remain constructive heading into the print. The company's Q1 results demonstrated resilience despite weather disruptions and tariff pressures, and the raised guidance signaled management confidence in the recovery trajectory. However, the narrow Q1 miss and margin compression have tempered expectations, with investors looking for evidence that operational execution can offset external headwinds.

Part 2: Historical Earnings Performance

Agilent has delivered a mixed but generally solid track record over the past four quarters. The company beat estimates in three of the last four reports, with surprises of +3.97% in Q2 2025, +0.74% in Q3 2025, and meeting estimates exactly in Q4 2025. The only miss came in the most recent Q1 2026 report, where the company fell short by -0.73% — a modest shortfall that still represented 4% year-over-year growth.

The pattern shows consistent execution with EPS climbing from $1.31 in Q2 2025 to $1.59 in Q4 2025 before moderating to $1.36 in Q1 2026, reflecting typical seasonal patterns in the laboratory instruments business. The magnitude of beats has been relatively modest, ranging from less than 1% to just under 4%, suggesting management provides realistic guidance rather than sandbagging estimates. The recent Q1 miss breaks a three-quarter streak of meets or beats, raising the stakes for the upcoming Q2 report to demonstrate that the company's raised full-year guidance remains achievable.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Agilent typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action shows significant volatility following Agilent earnings releases, with an average absolute Day +1 move of 3.53% and an average intraday range of 6.02%. The most dramatic reaction came after the May 2024 report, when the stock plunged 9.66% the following day. More recently, the February 2026 report triggered a 3.01% decline on Day +1 despite a modest 0.26% gain on Day 0, while the November 2025 report produced a 2.34% rally. The August 2025 report stands out with a 5.28% Day +1 surge, demonstrating the stock's capacity for sharp moves in either direction. Investors should prepare for meaningful price swings, as six of the last eight reports produced Day +1 moves exceeding 2%, and the average intraday range of 6.02% suggests substantial intraday volatility regardless of direction.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.28% for the June expiration, which is notably higher than the stock's average historical Day +1 move of 3.53% but closely aligned with the average Day +1 intraday range of 6.02%. This suggests options traders are anticipating above-average volatility for this particular release, potentially reflecting uncertainty around tariff impacts, margin trends, and the sustainability of the company's raised guidance.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Agilent, with an average rating of 4.44 out of 5.0 (solidly in Buy territory) and a consensus price target of $162.64 — implying 41% upside from the current price of $115.08. The rating breakdown shows strong conviction, with 11 Strong Buys, 1 Moderate Buy, and 4 Holds, while zero analysts rate the stock a Sell or Strong Sell.

Sentiment has remained unchanged over the past month, with the distribution of ratings holding steady at 11 Strong Buys, 1 Moderate Buy, and 4 Holds. The consistency suggests analysts are comfortable with their current views heading into the Q2 report, neither upgrading in anticipation of a strong print nor downgrading due to concern about execution risks.

The price target range spans from a low of $140.00 to a high of $185.00, with the mean target of $162.64 sitting comfortably in the middle. Even the most conservative $140.00 target implies 22% upside, while the high-end $185.00 target suggests potential for 61% gains if the company can deliver on its growth and margin expansion objectives. The wide target range reflects differing views on how quickly Agilent can navigate tariff headwinds and return to normalized margin levels, but the overall consensus remains decidedly positive.

Part 4: Technical Picture

Agilent's technical setup heading into earnings is cautious, with the Barchart Technical Opinion showing a 72% Sell signal — though notably improved from 88% Sell a week ago and 96% Sell a month ago. This weakening of the sell signal suggests some stabilization, but the stock remains under technical pressure.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative but is less severe than longer timeframes
• Medium-term (50% Sell): Moderate sell signal suggests consolidation or weakness persists in the intermediate timeframe
• Long-term (100% Sell): Strong sell signal reflects significant weakness in the longer-term trend, with the stock well below key moving averages

Trend Characteristics: The trend is rated as "Good" strength but "Weakening" direction, suggesting the downtrend remains intact but may be losing steam as the stock attempts to stabilize.

The stock is trading at $115.08, positioned above its 5-day ($113.84), 10-day ($113.19), 20-day ($114.06), and 50-day ($114.85) moving averages, indicating some short-term stabilization. However, the stock remains below its 100-day ($122.69) and 200-day ($129.41) moving averages, confirming the longer-term downtrend remains in force. The recent improvement in short-term moving average positioning suggests the stock may be attempting to form a base, but the 100-day and 200-day averages represent significant overhead resistance. The overall technical setup is cautionary heading into earnings — while short-term momentum has improved modestly, the stock would need a strong earnings beat and raised guidance to break through overhead resistance and reverse the longer-term bearish trend. Conversely, any disappointment could quickly erase recent stabilization gains and send the stock back toward recent lows.